drugset / Trial / NCT07250542

A Clinical Study on the Efficacy and Safety of Fasudil Hydrochloride Combined With Immunotherapy in the Treatment of Metastatic Castration-resistant Prostate Cancer

NCT07250542

Phase 2 Recruiting 30 enrolled baotai Liang
NaSingle-groupOpen-labelTreatment

Summary

Carrying out clinical trials of salbutamol hydrochloride combined with immunotherapy and castration for the treatment of prostate cancer is of great significance. Firstly, it can verify the efficacy and safety of this combination in the treatment of prostate cancer, providing a scientific basis for its clinical application. Secondly, through clinical trials, the mechanism of action of salbutamol hydrochloride combined with immunotherapy can be further studied. Finally, this clinical trial can further expand the treatment strategies for prostate cancer.

Timeline

Start
2024-07-05
Primary completion
2025-12-30
Completion
2026-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Fasudil Small molecule 10 mg Intravenous
Subject Tirapibep Monoclonal antibody 3 mg/kg Intravenous

Indications